ResMed Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +10.3%
EBITDA: +24.6%
EBIT: +17.8%
EPS: +16.0%
Free cash flow: +11.8%
Operating cash flow: +14.3%

Forward estimates

Revenue: +9.0%
EBITDA: +9.5%
EPS: +17.6%

Three-year CAGR

Revenue: +12.9%
EBITDA: +17.6%
EBIT: +19.0%
Net income: +21.6%
EPS: +21.4%
Free cash flow: +104.2%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.